2026 Holiday Shopping Study

Most Favored Nation (MFN) pricing and its impact on pharma asset valuation, M&A, and licensing

February 2, 2026

table {border-collapse: collapse;font-size: 12px;}table td {border: 1px solid black;padding: 5px;}table tr:first-child td img{display: inline-block;}table tr:first-child td p{display: inline-block;vertical-align: middle;}table tr:first-child td:nth-child(2) {background-color: #DAF5F5;color: #2DA1A1;}table tr:first-child td:nth-child(3) {background-color: #CBECFA;color: #0F7199;}table tr:first-chil

Transforming monetization approach to unlock growth in new segments

Most Favored Nation (MFN) pricing and its impact on pharma asset valuation, M&A, and licensing